GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (WBO:GMAB) » Definitions » YoY Rev. per Sh. Growth

Genmab AS (WBO:GMAB) YoY Rev. per Sh. Growth : 21.21% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genmab AS YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Genmab AS's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 was 21.21%.

Genmab AS's Revenue per Share for the three months ended in Sep. 2024 was €11.63.


Genmab AS YoY Rev. per Sh. Growth Historical Data

The historical data trend for Genmab AS's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS YoY Rev. per Sh. Growth Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.73 82.74 -16.92 72.35 13.53

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.14 -7.52 46.30 31.14 21.21

Genmab AS YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Genmab AS's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(33.532-29.537)/ | 29.537 |
=13.53 %

Genmab AS's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2024 )
=(Revenue per Share (Q: Sep. 2024 )-Revenue per Share (Q: Sep. 2023 )) / | Revenue per Share (Q: Sep. 2023 )) |
=(11.626-9.592)/ | 9.592 |
=21.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Genmab AS's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.